FutureMeds Poland aims to screen 22,000-23,000 at-risk patients for osteoporosis through our Stop Osteoporosis initiative this year. So far, more than 5500 women over 60 have received free DEXA screening and learned about fracture risk and osteoporosis. We launched the campaign in 4 cities in Poland in February 2023.
Every Friday and Saturday, working alongside the FutureMeds Wroclaw team, a German Shepherd called Disco provides additional support and calming presence for women over 60 who want to learn more about their risk of bone fracture.
This DEXA screening initiative aims to raise awareness and educate at-risk senior patient populations about osteoporosis, build trust in our service and grow our database of pre-screened patients who might be willing to volunteer in future Osteoporosis campaigns.
Launched in February 2023, the campaign is currently running in 4 cities in Poland. Patients can access DEXA screening via mobile units in Wroclaw, Warsaw, and Lodz. In Krakow, patients can visit our clinic for a free scan and learn more about their risk of osteoporosis.
The health impact of the Stop Osteoporosis Initiative
Osteoporosis is a major health problem in Europe, North America, Oceania, Asia & South America.
It is estimated that one in three women and one in five men over 50 suffer osteoporotic fractures. In fact, “an osteoporotic fracture occurs every three seconds”, according to the Global prevalence of Osteoporosis among older adults: a comprehensive systematic review and meta-analysis paper.
Osteoporosis is a silent thief of health, mobility and well-being among the ageing population. People tend to learn about bone density loss when it is too late. Raising awareness and talking about osteoporosis, therefore, is extremely important.
According to the current plans, our dedicated research site teams will be able to offer free DEXA scans and education to 22,000 - 23,000 at-risk patients in the surrounding patient communities throughout the year.
Patient engagement and trial benefits
Besides raising awareness and educating at-risk senior patient populations about osteoporosis, FutureMeds Poland also aims to build trust in our service and grow our database with pre-screened patients who might be willing to volunteer in future osteoporosis campaigns.
FutureMeds Poland’s Patient Engagement team conducted similar projects through 2020-2022. Our data from previous campaigns shows that approximately 12% of at-risk patients who participated in DEXA scans were diagnosed with osteoporosis.
“Thanks to initiatives similar to Stop Osteoporosis, FutureMeds sites in Poland can raise osteoporosis awareness, provide free diagnoses to at-risk patients and drive Osteoporosis study success.”
- Dr Radoslaw Janiak, CEO of FutureMeds
To reach the right target audience, Arkadiusz Kaspersk’s Patient Engagement team implemented a more engaging offline and online multichannel campaign. Current projections suggest that by the end of the year, over 2600 patients might be diagnosed with osteoporosis. Some of them might end up volunteering for osteoporosis studies in the future.
“So far, over 5500 at-risk elderly women have taken advantage of our free DEXA scans. I am proud that at FutureMeds, our teams can run similar campaigns that allow patients to receive early, high-quality diagnoses. The overwhelming response to our initiative is a testament to the fact that we are fulfilling a vital need in the community, and that's truly fulfilling for us.”
- Arkadiusz Kasperski, Head of Patient Engagement at FutureMeds
FutureMeds Osteoporosis Capability
FutureMeds sites are top recruiters for Osteoporosis studies, and on average, we overachieve our contractual targets by 30%. This performance is underscored by the expertise and know-how of our dedicated research site teams and the capability of our Clinical Research Specialists and Patient Engagement Team.
We have over 30 investigators with osteoporosis experience, who, in total, randomised over 1800 patients, and investigated 12 drugs and compounds throughout 46 osteoporosis studies.
Thanks to our large-scale DEXA pre-screening strategy, our growing specialist referrals network and cooperation with Patient Advocacy Groups, our sites’ FPI stats are commendable; FutureMeds Dedicated Research Sites can randomise patients 1 day after study activation.
Throughout the 2-3 months enrollment time, our sites enrol, on average, 30-60 patients into global studies with a target of over 450.
FutureMeds is a fast-growing independent Dedicated Research Site Network supporting pharmaceutical companies, Sponsors and CROs and contributing to research to find effective treatments and medications for all patients who need them.
FutureMeds’ Dedicated Research Site teams strive to accelerate study timelines, streamline processes, lower costs and improve data quality to help accelerate patient access to new treatments.
Through acquisitions and a strategic focus on patient experience, FutureMeds has developed qualified patient pools across Europe that enables faster patient enrollment and strong retention and help generate more accurate results.
Follow us on LinkedIn
Follow FutureMeds on LinkedIn and join a growing group of engaged, passionate healthcare and pharmaceutical professionals who are on a mission to accelerate the drug development process and achieve regulatory approval faster so patients can safely access the very latest treatments as soon as possible.